CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CAR-T 细胞治疗后恶性肿瘤的耐药与复发
英文原题：Resistance and recurrence of malignancies after CAR-T cell therapy.
查看英文原题
Resistance and recurrence of malignancies after CAR-T cell therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
CAR-T（CAR-T）细胞疗法的出现开启了癌症治疗的新时代，尤其是血液系统恶性肿瘤的治疗。然而，部分患者在接受CAR-T 细胞治疗后仍会出现耐药和复发。CAR-T 细胞效力不足和肿瘤逃逸已成为这种前景广阔的免疫疗法在B细胞恶性肿瘤长期疾病控制中的主要挑战。在实体瘤治疗中，CAR-T 细胞还必须克服来自肿瘤或免疫抑制性肿瘤环境的诸多障碍，这些已成为CAR-T 疗法进步的阻碍。因此，了解患者CAR-T 治疗后失败的机制十分必要。在本综述中，我们描述了CAR-T 细胞治疗后耐药和复发的一些机制，并相应地提出了合理的治疗策略。
展开英文摘要原文
The emergence of chimeric antigen receptor T (CAR-T) cell therapy has ushered a new era in cancer therapy, especially the treatment of hematological malignancies.
However, resistance and recurrence still occur in some patients after CAR-T cell treatment. CAR-T cell inefficiency and tumor escape have emerged as the main challenges for the long-term disease control of B cell malignancies by this promising immunotherapy. In solid tumor treatment, CAR-T cells must also overcome many hurdles from the tumor or immune-suppressed tumor environment, which have become obstacles to the advancement of CAR-T therapy.
Therefore, an understanding of the mechanisms underlying post-CAR treatment failure in patients is necessary. In this review, we characterize some mechanisms of resistance and recurrence after CAR-T cell therapy and correspondingly suggest reasonable treatment strategies.
论文信息
- 作者
- Zeng W、Zhang P
- 第一作者单位
- National Center for International Research of Bio-targeting Theranostics, Guangxi Key Laboratory of Bio-targeting Theranostics, Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Talent Highland of Bio-targeting Theranostics, Guangxi Medical University, Nanning, Guangxi, 530021, China.China
- 通讯作者单位
- National Center for International Research of Bio-targeting Theranostics, Guangxi Key Laboratory of Bio-targeting Theranostics, Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Talent Highland of Bio-targeting Theranostics, Guangxi Medical University, Nanning, Guangxi, 530021, China; Zhejiang Provincial Key Laboratory of Pancreatic Disease, The First Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang Province, 310003, China; Institute of Translational Medicine, Zhejiang University Medical School, Hangzhou, Zhejiang Province, 310058, China. Electronic address: pzhangbcmedu@gmail.com.China
- 文献类型
- 非美国政府资助研究 · 综述
- 期刊
- Experimental cell research2022 Jan 15
- 原文标识
- PubMed 34906583 · DOI 10.1016/j.yexcr.2021.112971